Stocks · News reference
Wall Street analysts changed outlook on top stocks. To see all changes, visit the analyst ratings page. FAST stock has a Buy rating with $55 PT.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-07 AccNo: 0001493152-26-036557 Size: 421 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the
Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
Filed: 2026-07-16 AccNo: 0000815556-26-000043 Size: 149 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Fastenal (NASDAQ:FAST) reported in-line Q2 earnings, with sales up 14.7% to $2.387B. Analysts maintain ratings and price targets on stock.
Morgan Stanley analyst Chris Snyder maintains Fastenal (NASDAQ:FAST) with a Equal-Weight and raises the price target from $48 to $52.